Hang Yuan1, Ai-Jun Li1, Sen-Lin Ma1, Long-Jiu Cui1, Bin Wu1, Lei Yin1, Meng-Chao Wu1. 1. Hang Yuan, Ai-Jun Li, Sen-Lin Ma, Long-Jiu Cui, Bin Wu, Lei Yin, Meng-Chao Wu, Department of the 2 Special Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China.
Abstract
AIM: To clarify whether histone deacetylase inhibitors histone deacetylase inhibitors (HDACIs) can sensitize hepatocellular carcinoma (HCC) cells to sorafenib treatment. METHODS: Bax, Bcl-2, ATG5-ATG12, p21, and p27 protein levels in Hep3B, HepG2, and PLC/PRF/5 cells were examined by Western blot. CCK8 and a fluorometric caspase-3 assay were used to examine cellular viability and apoptosis levels. The effect of Beclin-1 on sensitization of HCC cells to sorafenib was examined by transfecting Beclin-1 siRNA into Hep3B, HepG2, and PLC/PRF/5 cells. RESULTS: Autophagy inhibition enhances the inhibitory effects of vorinostat and sorafenib alone or in combination on HCC cell growth. Vorinostat and sorafenib synergistically induced apoptosis and cell cycle alterations. Western blot data indicated that HDACIs and Beclin-1 knockdown increased the p53 acetylation level. The knockdown of Beclin-1 enhanced the synergistic effect of the combination of vorinostat with sorafenib. CONCLUSION: HDACIs can sensitize HCC cells to sorafenib treatment by regulating the acetylation level of Beclin-1.
AIM: To clarify whether histone deacetylase inhibitors histone deacetylase inhibitors (HDACIs) can sensitize hepatocellular carcinoma (HCC) cells to sorafenib treatment. METHODS:Bax, Bcl-2, ATG5-ATG12, p21, and p27 protein levels in Hep3B, HepG2, and PLC/PRF/5 cells were examined by Western blot. CCK8 and a fluorometric caspase-3 assay were used to examine cellular viability and apoptosis levels. The effect of Beclin-1 on sensitization of HCC cells to sorafenib was examined by transfecting Beclin-1 siRNA into Hep3B, HepG2, and PLC/PRF/5 cells. RESULTS: Autophagy inhibition enhances the inhibitory effects of vorinostat and sorafenib alone or in combination on HCC cell growth. Vorinostat and sorafenib synergistically induced apoptosis and cell cycle alterations. Western blot data indicated that HDACIs and Beclin-1 knockdown increased the p53 acetylation level. The knockdown of Beclin-1 enhanced the synergistic effect of the combination of vorinostat with sorafenib. CONCLUSION: HDACIs can sensitize HCC cells to sorafenib treatment by regulating the acetylation level of Beclin-1.
Authors: Viola Baradari; Alexander Huether; Michael Höpfner; Detlef Schuppan; Hans Scherübl Journal: Endocr Relat Cancer Date: 2006-12 Impact factor: 5.678
Authors: Andreas P Sutter; Kerstin Maaser; Patricia Grabowski; Gesine Bradacs; Kirsten Vormbrock; Michael Höpfner; Antje Krahn; Bernhard Heine; Harald Stein; Rajan Somasundaram; Detlef Schuppan; Martin Zeitz; Hans Scherübl Journal: J Hepatol Date: 2004-11 Impact factor: 25.083
Authors: Christoph Herold; Marion Ganslmayer; Matthias Ocker; Martin Hermann; Albert Geerts; Eckhart G Hahn; Detlef Schuppan Journal: J Hepatol Date: 2002-02 Impact factor: 25.083
Authors: C Verslype; E Van Cutsem; M Dicato; N Arber; J D Berlin; D Cunningham; A De Gramont; E Diaz-Rubio; M Ducreux; T Gruenberger; D Haller; K Haustermans; P Hoff; D Kerr; R Labianca; M Moore; B Nordlinger; A Ohtsu; P Rougier; W Scheithauer; H-J Schmoll; A Sobrero; J Tabernero; C van de Velde Journal: Ann Oncol Date: 2009-06 Impact factor: 32.976
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312
Authors: Nestor Prieto-Domínguez; Raquel Ordóñez; Anna Fernández; Andres García-Palomo; Jordi Muntané; Javier González-Gallego; José L Mauriz Journal: Front Pharmacol Date: 2016-06-08 Impact factor: 5.810